European countries need to discontinue prescribing older, suboptimal drugs to treat hepatitis B virus (HBV) as the virus has become drug resistant, a new study shows.
According to the results of the study published in The Journal of Infectious Diseases, doctors in Europe have been prescribing old antiviral drugs, which in turn is also likely to result in creating resistance to modern compounds. The report has called for putting a stop to prescribing nucleos(t)ide analogues (NAs) as the only way to end the development of drug-resistant hepatitis B virus.
Older NAs are still being prescribed in European countries in face of limited access to newer NAs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze